SCHEMBL3430294

SCHEMBL3430294

O=C(Nc1ccc2c(c1)OCO2)c1nn(Cc2ccc(S(=O)(=O)N3CCOCC3)cc2)c2ccccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.55
MAPT P10636 1/20 0.55
HPGD P15428 1/20 0.55
LMNA P02545 4/20 0.54
KMT2A Q03164 3/20 0.54
MEN1 O00255 2/20 0.53
PTPN7 P35236 1/20 0.52
NPSR1 Q6W5P4 1/20 0.51
RXFP1 Q9HBX9 1/20 0.51
NPC1 O15118 4/20 0.51
RAB9A P51151 2/20 0.51
USP2 O75604 1/20 0.51
TP53 P04637 1/20 0.51
MAPK1 P28482 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
POLB P06746 1/20 0.49
GAA P10253 1/20 0.49
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3432205 0.87 RAB9A (0.51) ALDH1A1MAPTKMT2AMEN1NPSR1
SCHEMBL3430712 0.86 RAB9A (0.52) ALDH1A1MAPTKMT2AMEN1NPSR1
SCHEMBL3760296 0.85 NPC1 (0.57) ALDH1A1MAPTHPGDLMNANPSR1
SCHEMBL13051112 0.85 IDH1 (0.54) ALDH1A1MAPTKMT2AMEN1NPSR1
SCHEMBL3406432 0.85 RAB9A (0.61) ALDH1A1MAPTLMNAKMT2AMEN1
SCHEMBL3429942 0.85 TSHR (0.57) ALDH1A1MAPTKMT2AMEN1NPSR1
SCHEMBL3428179 0.85 RAB9A (0.49) ALDH1A1MAPTKMT2AMEN1NPSR1
SCHEMBL3427388 0.85 RAB9A (0.49) ALDH1A1MAPTLMNAKMT2AMEN1
SCHEMBL3430447 0.85 KMT2A (0.54) ALDH1A1MAPTLMNAKMT2AMEN1
SCHEMBL3426277 0.83 RAB9A (0.57) ALDH1A1MAPTLMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257340-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-12-08 EP claimed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US claimed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO claimed
EP-2257340-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-12-08 EP disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY CPT1B, SMN1; SMN2, GYS1 ALDH1A1 359/4885MAPT 3715/4885HPGD 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.